表紙
市場調査レポート

アジア太平洋地域の骨粗鬆症治療薬市場

Osteoporosis Drugs Market in the APAC Region 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 320962
出版日 ページ情報 英文 73 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
アジア太平洋地域の骨粗鬆症治療薬市場 Osteoporosis Drugs Market in the APAC Region 2015-2019
出版日: 2014年12月03日 ページ情報: 英文 73 Pages
概要

骨粗鬆症は特に症状が無いため、骨折するまでは判明しないことが往々にしてあります。この疾患のリスク要因として、加齢、性ホルモンの減少や更年期、喫煙などが挙げられます。アジア太平洋地域における骨粗鬆症治療薬市場の2014年から2019年のCAGR(複合年間成長率)は、4.73%が見込まれています。

当レポートでは、アジア太平洋地域における骨粗鬆症治療薬市場の現況および今後の成長見通しの分析、パイプラインの概要、薬剤クラス別の動向、主要治療薬の評価、市場の発展要因と課題、主要ベンダーの分析などを提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品
    • 製品プロファイル

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第7章 パイプラインの概要

第8章 疫学と人口統計

  • 中国
  • 香港
  • 日本
  • インド

第9章 薬剤クラス別の市場区分

第10章 主要医薬品の市場評価

  • Prolia
  • Fosamax
  • Evista
  • Forteo
  • Zometa

第11章 購入基準

第12章 市場成長因子

第13章 成長因子とその影響

第14章 市場の課題

第15章 成長因子と課題の影響

第16章 市場動向

第17章 動向とその影響

第18章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • M&A
  • 市場シェア分析
  • その他の有力ベンダー

第19章 主要ベンダーの分析

  • Amgen
  • Eli Lilly
  • Merck & Co. Inc.
  • Novartis AG

第20章 関連レポート

目次
Product Code: IRTNTR4777

About Osteoporosis

Osteoporosis is a disease that reduces of the mass and density of bone, and results in increased risk of fracture. In this disease, the risks related to fracture increases because of the increased permeability of the bones. Often, there are no symptoms observed until the first fracture occurs. Increase in age, low body weight, low sex hormones or menopause, and smoking are some of the risk factors associated with this disease.

TechNavio's analysts forecast the Osteoporosis Drugs market in APAC to grow at a CAGR of 4.73 percent over the period 2014-2019.

Covered in this Report

The Osteoporosis Drugs market in APAC can be divided into two segments: Antiresorptives and Anabolics. This report covers the present scenario and the growth prospects of the Osteoporosis Drugs market in APAC for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various osteoporosis drugs that are available in the market.

TechNavio's report, the Osteoporosis Drugs market in APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Osteoporosis Drugs market in APAC landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

  • Amgen
  • Eli Lilly
  • Merck
  • Novartis

Other Prominent Vendors

  • F. Hoffmann La Roche
  • GlaxoSmithKline
  • Jiangsu Hengrui Medicine
  • Pfizer Inc.
  • Qingdao Chiatai Haier Pharmaceutical  

Market Driver

  • Increasing Global Aging Population
  • For a full, detailed list, view our report

Market Challenge

  • Multiple Patent Expiries
  • For a full, detailed list, view our report

Market Trend

  • Increasing Awareness of Bone Health Education
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • 03.2.1. Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Pipeline Snapshot

08. Epidemiology and Demography

    • 08.1.1. China
    • 08.1.2. Hong Kong
    • 08.1.3. Japan
    • 08.1.4. India

09. Market Segmentation by Drug Class

10. Market Assessment of Top Drugs

  • 10.1. Prolia
    • 10.1.1. Sales
  • 10.2. Fosamax
    • 10.2.1. Sales
  • 10.3. Evista
    • 10.3.1. Sales
  • 10.4. Forteo
    • 10.4.1. Sales
  • 10.5. Zometa
    • 10.5.1. Sales

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2013
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Amgen
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Business Segmentation by Revenue 2013
    • 19.1.4. Product Portfolio by Revenue 2013
    • 19.1.5. Business Segmentation by Revenue 2012 and 2013
    • 19.1.6. Geographical Segmentation by Revenue 2013
    • 19.1.7. Business Strategy
    • 19.1.8. Recent Developments
    • 19.1.9. SWOT Analysis
  • 19.2. Eli Lilly
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Segmentation by Revenue
    • 19.2.4. Sales by Geography
    • 19.2.5. Business Strategy
    • 19.2.6. Key Information
    • 19.2.7. SWOT Analysis
  • 19.3. Merck & Co. Inc.
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation by Revenue 2013
    • 19.3.4. Business Segmentation by Revenue 2012 and 2013
    • 19.3.5. Sales by Geography
    • 19.3.6. Business Strategy
    • 19.3.7. Key Developments
    • 19.3.8. SWOT Analysis
  • 19.4. Novartis AG
    • 19.4.1. Key Facts
    • 19.4.2. Business Description
    • 19.4.3. Business Segmentation
    • 19.4.4. Revenue by Business Segmentation
    • 19.4.5. Revenue Comparison 2012 and 2013
    • 19.4.6. Sales by Geography
    • 19.4.7. Business Strategy
    • 19.4.8. Key Developments
    • 19.4.9. SWOT Analysis

20. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Osteoporosis Drugs Market in APAC 2013-2018 (US$ billion)
  • Exhibit 3: Clinical Trial Map of Conjugated Estrogens/Bazedoxifene
  • Exhibit 4: Clinical Trial Map of Viviant
  • Exhibit 5: Clinical Trial Map of Prolia
  • Exhibit 6: Clinical Trial Map of Romosozumab
  • Exhibit 7: Clinical Trial Map of LY2541546 (Blosozumab)
  • Exhibit 8: Population Increase in People Aged 50 Years Or Over By Country (million), 2013 to 2019
  • Exhibit 9: Osteoporosis Drugs Market in APAC Segmentation by Drug Class
  • Exhibit 10: Antiresorptives Drugs Segmentation
  • Exhibit 11: Bisphosphonates Drugs Segmentation
  • Exhibit 12: Amgen's Prolia Global Revenue 2010-2013 (US$ million)
  • Exhibit 13: Merck's Fosamax Global Revenue 2009-2012 (US$ million)
  • Exhibit 14: Eli Lilly's Evista Global Revenue 2010-2013 (US$ million)
  • Exhibit 15: Eli Lilly's Forteo Global Revenue 2010-2013 (US$ million)
  • Exhibit 16: Novartis Zometa Global Revenue 2010-2013 (US$ million)
  • Exhibit 17: Amgen: Business Segmentation by Revenue 2013
  • Exhibit 18: Amgen: Product Portfolio by Revenue 2013
  • Exhibit 19: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 20: Amgen: Geographical Segmentation by Revenue 2013
  • Exhibit 21: Eli Lilly: Business Segmentation by Revenue 2013
  • Exhibit 22: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 23: Eli Lilly: Sales by Geography 2013
  • Exhibit 24: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 25: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 26: Merck & Co. Inc.: Sales by Geography 2013
  • Exhibit 27: Novartis AG: Business Segmentation
  • Exhibit 28: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 29: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 30: Novartis AG: Revenue by Geographical Segmentation 2013
Back to Top